Head-to-head evidence
HPP737 vs roflumilast
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
HPP737
Developed by Newsoara Biopharma
NCT07712731 · Phase 3 · completed
The trial randomized 607 participants to HPP737 or active treatment with apremilast and used triple masking of participants, care providers, and investigators. Its primary endpoints were clinical psoriasis measures, but the treatment comparison cannot yet be judged because the registry has not posted results.
roflumilast · Zoryve
Marketed by Arcutis Biotherapeutics
NCT06648772 · Phase 3 · completed
The study randomly assigned 190 participants to roflumilast cream or vehicle cream and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a clinical psoriasis severity measure, but whether that endpoint was met cannot be determined because results are not available.
Next expected readout: July 2027 · NCT07725822 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HPP737's landscape · roflumilast's landscape